1. Home
  2. ESPR vs BTX Comparison

ESPR vs BTX Comparison

Compare ESPR & BTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.70

Market Cap

660.1M

Sector

Health Care

ML Signal

HOLD

Logo BlackRock Technology and Private Equity Term Trust Common Shares of Beneficial Interest

BTX

BlackRock Technology and Private Equity Term Trust Common Shares of Beneficial Interest

HOLD

Current Price

$6.77

Market Cap

773.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESPR
BTX
Founded
2008
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
660.1M
773.8M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ESPR
BTX
Price
$3.70
$6.77
Analyst Decision
Buy
Analyst Count
7
0
Target Price
$6.86
N/A
AVG Volume (30 Days)
7.0M
938.4K
Earning Date
11-06-2025
11-01-2025
Dividend Yield
N/A
13.82%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$303,802,000.00
N/A
Revenue This Year
$25.45
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.83
N/A
52 Week Low
$0.69
$5.10
52 Week High
$4.03
$8.31

Technical Indicators

Market Signals
Indicator
ESPR
BTX
Relative Strength Index (RSI) 63.61 52.33
Support Level $3.59 $6.66
Resistance Level $3.91 $6.90
Average True Range (ATR) 0.24 0.17
MACD 0.05 0.03
Stochastic Oscillator 77.74 82.30

Price Performance

Historical Comparison
ESPR
BTX

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

About BTX BlackRock Technology and Private Equity Term Trust Common Shares of Beneficial Interest

BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.

Share on Social Networks: